Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Novo Nordisk holds ~35% volume market share of the basal market in the USA Slide 8 Weekly TRX volume market shares¹ in the USA - glargine U100 Basal volume TRX MS 70% 60% 50% 40% 30% 20% 10% 0% Mar 2016 NN Total Basal TresibaⓇ LevemirⓇ glargine U300 biosimilar glargine U100 42.2% 34.8% 22.8% 11.8% 8.5% 8.4% Mar 2018 TresibaⓇ launch in the USA • TresibaⓇ TRX volume market share is now 11.8% • Main market share driver in Q1 2018 has been the formulary change at CVS part D¹ ⚫ TresibaⓇ formulary access is now estimated to be around 80%² for Commercial and Medicare Part D combined, following formulary access on United Health Care Part D ⚫ TresibaⓇ label in the USA updated to include cardiovascular safety data and 40% reduction of severe hypoglycaemic events compared to insulin glargine U100. The updated TresibaⓇ label was launched mid-April 2018 in the USA Note: The graph does not show NPH, which accounts for the residual market share Source: IQVIA weekly Xponent Plantrak, 23 March 2018 ¹Excludes Medicaid that represents ~12% of retail basal market volume and basal insulin and GLP-1 combination products such as XultophyⓇ TRX volume: Insulin volume in mega units (MU) associated with total number of prescriptions; MS: Market share Source: IQVIA weekly Xponent Plantrak, 23 March, 2018 1 CVS formulary Silverscript 2 Projected access calculated from VANTAGE FingerTip Formulary bridge February 2018, week ending 2 March 2018. novo nordisk

View entire presentation